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BACKGROUND: Our recent work has shown the feasibility of using a refined immunomagnetic enrichment (IE) assay to detect
cytokeratin 20-positive circulating tumour cells (CK20 pCTCs) in colorectal cancer (CRC) patients. We attempted to improve the
sensitivity for CRC by detecting another intestinal-type differentiation marker, CDX2 pCTCs, using the same methodology.
METHODS: CDX2 pCTCs were detected in patients with CRC, colorectal adenoma (CAD), benign colorectal diseases (BCD), other
common cancers (OCC) and normal subjects (NS). Statistical analysis was used to correlate CDX2 pCTCs to the
clinicohistopathological factors, recurrence, metastasis and survival after follow-up for 42 months in CRC patients.
RESULTS: CDX2 pCTCs were detected in 81% CRC patients (73 out of 90, median number¼21.5 CTCs), 7.5% CAD patients (3 out
of 40), 0% patients with BCD (0 out of 90), 2.5% patients with OCC (2 out of 80) and 0% NS (0 out of 40). Furthermore, statistical
analysis showed that CDX2 pCTC numbers were associated with tumour- node-metastasis stage and lymph node status. Using the
median CDX2 pCTC numbers as the cutoff points, stratified groups of CRC patients had significant differences in their recurrence
and survival.
CONCLUSIONS: This study showed that the refined IE assay can detect CDX2 pCTCs with high sensitivity and that CDX2 pCTCs can
generate clinically important information for CRC patients.
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The identification of circulating tumour cells (CTCs) can be used
to detect malignancy, predict metastasis, evaluate prognosis, assist
in the management of cancer patients and monitor recurrence and
metastasis after primary therapy (Braun and Naume, 2005;
Mocellin et al, 2006; Paterlini-Brechot and Benali, 2007; Sleijfer
et al, 2007). Approaches to detect CTCs can be classified into
molecular-based methods, which detect target mRNA expression,
and cytometric methods, which isolate and quantify individual
cells (Paterlini-Brechot and Benali, 2007). Although researchers
have reached an important consensus that cytopathological
examination of CTCs after immunomagnetic enrichment (IE),
with further characterisation of their malignant potential, repre-
sents a promising approach (Cristofanilli et al, 2004, 2006), the
current IE method uses either a broad-spectrum anti-cytokeratin
(CK) antibody (Miltenyi Biotec, Bergisch Gladbach, Germany),
combined anti-CK8, anti-CK18 and anti-CK19 antibodies (Cell-
Search system, Veridex, Warren, NJ, USA) or an anti-BerEP4
antibody (Dynal Biotech, Invitrogen, Carlsbad, CA, USA) against
general epithelial antigens of various tumour and normal cells.
Therefore, specific information on the primary tumour type is not
available. Our recent work has overcome this limitation by
blocking the Fc region of the anti-BerEP4 antibody with a goat
anti-mouse antibody during IE, so that an anti-CK20 antibody can
be used to show the gastrointestinal (GI) origin of the BerEP4-
positive cells in the blood of colorectal cancer (CRC) patients
(Wong et al, 2009). This modification can improve immunomag-
netic CTC detection by allowing tumour- or tissue-specific
antibodies to bind to their respective antigens so that an accurate
diagnosis of the tumour type can be made. As the detection rate of
CK20-positive circulating tumour cells (CK20 pCTCs) in CRC was
only 62% (Wong et al, 2009), we aimed to improve the sensitivity
for CRC by detecting another intestinal-type differentiation
marker, CDX2 pCTCs, using the same methodology. CDX2 has
critical functions in intestinal development, differentiation and
maintenance of the intestinal phenotype (Takakura et al, 2010).
Moreover, CDX2 is a more specific marker than CK, CK8, CK18,
CK19 and BerEP4 because the former antigen is expressed mainly
in tumour and normal cells from the GI tract, whereas the latter
antigens are expressed in virtually all carcinomas and all non-
neoplastic epithelial cells (Latza et al, 1990; Chu and Weiss, 2002).
Therefore, we expect that CDX2 pCTCs may more accurately
reflect the micrometastatic condition of the CRC patients. In this
study, the refined assay was used to evaluate the clinical
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ssignificance of CDX2 pCTCs in CRC by detecting such cells in
patients with CRC, colorectal adenoma (CAD), benign colorectal
diseases (BCD) and other common cancers (OCC). We further
correlated CDX2 pCTC numbers to the clinicohistopathological
factors, recurrence, metastasis and survival after follow-up for 42
months. The information obtained in this study would be very
useful for understanding the prognostic and diagnostic potential of
CDX2 pCTCs in CRC patients.
MATERIALS AND METHODS
Blood samples of patients
Between March 2003 and August 2007, blood samples were taken
from three cohorts of patients. In the first cohort, blood samples
from 90 CRC patients and 40 CAD patients were taken at two time
points: (1) before operation (stages I–III CRC patients on the basis
of tumour node metastasis (TNM) classification), before thera-
peutic intervention (TNM stage IV CRC patients) and before
endoscopy (CAD patients) and (2) on first follow-up (7 days after
operation for CRC patients and 7 days after endoscopy for CAD
patients). Moreover, 64 TNM stages I–III CRC patients were
followed up for 42 months from their respective diagnosis for
recurrent or metastatic CRC and the disease-free survival (DFS) in
patients with (1) negative preoperative CDX2 pCTC, (2) positive
preoperative CDX2 pCTCs and decreased postoperative level and
(3) positive preoperative CDX2 pCTCs and increased postoperative
level, were compared separately. Furthermore, overall survival
(OS) in 90 TNM stages I–IV CRC patients using the median
number of pretreatment CDX2 pCTC as the cutoff point was
studied. As the TNM stage IV patients in our cohort did not receive
curative treatment, the OS of 64 TNM stages I–III CRC patients
using the median number of preoperative CDX2 pCTC as the
cutoff point was also compared. In the second cohort, blood
samples from 30 patients each with colitis, haemorrhoids, colo-
rectal ulcers and hyperplastic polyps were taken before surgical
treatment. In the third cohort, blood samples from 20 patients each
with breast cancer, prostate cancer, liver cancer and lung cancer
were taken before operation or treatment. We evaluated all CRC
patients preoperatively by routinely performing a computerised
tomography (CT) in the abdomen and pelvis before surgery in
order to rule out liver metastasis, peritoneal deposits or
lymphadenopathy. In addition, positron emission tomography
(PET) scan was performed in CRC patients when there was an
uncertainty in metastasis. In patients with increased postoperative
CDX2 pCTCs, CT and PET scans were used to search for residual
disease. Finally, 40 normal subjects (NS) were also recruited for
comparison. Although the NS did not undergo colonoscopy to
confirm their status, their plasma samples had been tested for
carcinoembryonic antigen (CEA) protein and all were within the
normal range. Informed consent was obtained from all patients
and healthy individuals. The clinicohistopathological character-
istics of the studied subjects were shown in Table 1. The study was
approved by the Clinical Research Ethics Committee of the Prince
of Wales Hospital and Queen Elizabeth Hospital, Hong Kong
Special Administrative Region.
Refined IE assay, immunocytochemical (ICC) staining and
examination of CDX2 pCTCs in blood samples
Ten millilitres of blood from each sample was collected in EDTA
tubes. The mononuclear cells were collected by centrifugation
through a Ficoll density gradient (catalogue no. 17-1440-02; GE
Healthcare, Uppsala, Sweden), according to the manufacturer’s
instructions. The CTCs were isolated from the mononuclear cells
using the refined protocol as shown in our recent study (Wong
et al, 2009) and CDX2 ICC staining was performed for each patient
sample. The criteria used to identify CDX2 pCTCs in a blood
sample were as follows: (1) positive CDX2 staining, (2) the cell
should have a round-to-oval morphology and (3) the cell size
should be at least double that of a lymphocyte. The CDX2 pCTCs
were examined and quantified by two independent assessors and
an average cell number was calculated for each patient sample.
Statistical analysis
Multivariate regression was used to analyse whether preoperative
CDX2 pCTCs were correlated with the clinicohistopathological
factors of the patients and Cox’s proportional hazards model was
applied to detect the independent prognostic factors of survival
(Statistical Package for the Social Sciences Version 12.0 software,
SPSS Inc., Chicago, IL, USA). Besides, w
2 test was used to examine
the association between preoperative CDX2 pCTCs and recurrent
or metastatic CRC. Kaplan–Meier method was used to plot the OS
and DFS curves and log-rank test was used to examine whether the
Table 1 Clinicohistopathological characteristics of studied subjects
Colorectal carcinoma patients (n¼90)
Sex
Male 59 (66%)
Female 31 (34%)
Age (years)
Range 26–91
Median 67
TNM classification
Tumour stage
T1 14 (16%)
T2 26 (29%)
T3 29 (32%)
T4 21 (23%)
Lymph node status
N0 41 (46%)
N1 23 (25%)
N2 26 (29%)
TNM stage
Stage I 19 (21%)
Stage II 22 (24%)
Stage III 23 (26%)
Stage IV 26 (29%)
Degree in differentiation
Well 15 (17%)
Moderate 51 (57%)
Poor 24 (26%)
Colorectal adenoma patients (n¼40)
Sex
Male 22 (55%)
Female 18 (45%)
Age (years)
Range 26–78
Median 53
Degree in dysplasia
Mild 6 (15%)
Moderate 23 (58%)
Severe 11 (27%)
Apparently normal subjects (n¼40)
Sex
Male 19 (48%)
Female 21 (52%)
Age (years)
Range 22–70
Median 34
Abbreviation: TNM¼tumour node metastasis.
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preoperative CDX2 pCTCs had significant difference (GraphPad
Prism software version 4.0, GraphPad, Software Inc., San Diego,
CA, USA). A P-value o0.05 was considered to be statistically
significant.
RESULTS
CDX2 pCTCs in patients with CRC, CAD and NS
CDX2 pCTC cannot be found in any of the 40 NS (Figure 1A);
therefore, the baseline was set at 0 CTC and detection of X1 CTC
per 10-ml blood was considered to be positive. Detailed analysis
showed that the overall detection rate in CRC, CAD patients and
NS were 81% (73 out of 90, range: 0–351), 7.5% (3 out of 40, range:
0–8) and 0% (0 out of 40), respectively (Figure 1A). When we
divided the CRC patients into different TNM stages, the detection
rates were 63% (12 out of 19, stage I), 77% (17 out of 22, stage II),
87% (20 out of 23, stage III) and 92% (24 out of 26,
stage IV) (Figure 1B). On their first follow-up, only 64 CRC
patients (stages I–III) were recruited because 26 patients with
stage IV did not undergo surgery. Among them, 49 patients (49 out
of 64¼77%) had detectable preoperative CDX2 pCTCs and 35 of
49 patients (71%) were found to have a decreased number of
postoperative CDX2 pCTCs, whereas 9 of 49 (18%) patients had
increased number of postoperative CDX2 pCTCs (Figure 1C). In
contrast, only three CAD patients had detectable preendoscopy
CDX2 pCTCs and none of them showed any CDX2 pCTCs after
endoscopy. A typical CDX2 pCTC from a CRC patient was shown
in Figure 2.
Multivariate regression analysis
Multivariate regression analysis was applied to examine whether
pretreatment CDX2 pCTCs was correlated with the clinicohisto-
pathological factors of the 90 TNM stages I–IV CRC patients.
Significant associations were found with TNM stage (Po0.001)
and lymph node status (Po0.01) but not for age (P¼0.672), sex
(P¼0.854), tumour stage (P¼0.385) and degree of differentiation
(P¼0.316).
Recurrent or metastatic CRC
The median number of preoperative CDX2 pCTCs from the 64
TNM stages I–III CRC patients was 13.5. Using this median
number as the cutoff point, 10 patients with preoperative CDX2
pCTCs 413.5 and only three patients with preoperative CDX2
pCTCs p13.5 had recurrent or metastatic CRC after follow-up for
42 months and the association between preoperative CDX2 pCTCs
and recurrent or metastatic CRC was highly significant (w
2 test:
w
2¼4.73; Po0.05).
Survival of CRC patients
Overall survival curves were plotted for patients with pretreatment
CDX2 pCTCs 421.5 and those with pretreatment CDX2 pCTCs
p21.5, where 21.5 is the median number of pretreatment CDX2
pCTCs from the first cohort of 90 CRC patients. Our results
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Figure 1 CDX2 pCTCs in blood samples. (A) Number of CDX2
pCTCs per 10-ml blood sample in 90 CRC patients (preoperation), 40
CAD patients (preendoscopy) and 40 NS. (B) Number of CDX2 pCTCs
per 10-ml blood sample in 19 stage I, 22 stage II, 23 stage III and 26 stage IV
CRC patients. (C) Number of CDX2 pCTCs per 10-ml blood sample in 64
CRC patients (preoperation and first follow-up) with interconnecting lines
between the two time points. The median in each group of subjects is
indicated by a black horizontal line.
CDX2 pCTC
MHC
50.0 m
Figure 2 A typical CDX2 pCTC from a CRC patient sample. MHC:
mononuclear hematopoietic cell (original magnification,  400).
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sshowed that the survival rates for those two groups of patients
were significantly different (Po0.0001, log-rank test; Figure 3).
Moreover, the independent prognostic factors of OS identified by
the Cox’s proportional hazards regression model were found to be
pretreatment CDX2 pCTCs (P¼0.003) and lymph node status
(P¼0.022; Table 2). Furthermore, the OS in stages I–III patients
stratified by the median number of preoperative CDX2 pCTCs of
13.5 had significant difference (Po0.05, log-rank test; Figure 4).
Among the nine patients who had increased postoperative number
of CDX2 pCTCs, two were stage III and seven were stage II. Follow-
up for 42 months showed that one stage III patient and two stage II
patients died of disease, whereas one stage III patient and two stage
II patients had disease progression of either recurrence or
metastasis. Stratifying the patients into subgroups indicated
significant differences in DFS between (a) patients with negative
preoperative CDX2 pCTCs and those with positive preoperative
CDX2 pCTCs and increased postoperative level (Po0.001, log-
rank test; Figure 5) and (b) patients with positive preoperative
CDX2 pCTCs and decreased postoperative level and those with
positive preoperative CDX2 pCTCs and increased postoperative
level (Po0.005, log-rank test; Figure 5).
CDX2 pCTCs in patients with BCD and OCC
Pretreatment CDX2 pCTCs can be detected in none of the patients
with BCD (colitis, haemorrhoids, colorectal ulcers and hyperplastic
polyps) and 2.5% (2 out of 80) patients with other OCC (breast
cancer, prostate cancer, liver cancer and lung cancer).
DISCUSSION
Although the clinical significance of CTCs from patients with
tumours is still debatable (Giribaldi et al, 2006; Katsumata et al,
2006), the technology platform has improved rapidly. Over the last
few years, CTC detection has become more standardised and
reliable (Naoe et al, 2007; Riethdorf et al, 2007). A typical example
is the detection of CTCs with the CellSearch System, which allows
the defined stratification of the risk of death in metastatic breast
cancer patients (Cristofanilli et al, 2005). However, the anti-CK
antibody panel (CK8, CK18 and CK19) in this system is not specific
in tumour typing. Therefore, we hypothesise that the detection of a
specific marker in CTCs with quantification might be helpful in the
prognosis and diagnosis of CRC patients.
Table 2 Multivariate regression for overall survival by Cox’s proportional hazards regression
Parameter P-value Relative hazard 95% CI for relative hazard
Preoperative CDX2 pCTCs (421.5 and p21.5) 0.003 (S) 9.274 4.372–12.795
Sex (male vs female) 0.651 (NS) — —
Age (471 vs p71 years) 0.949 (NS) — —
pT category (T1+T2 vs T3+T4) 0.752 (NS) — —
Differentiation (well vs poor) 0.816 (NS) — —
Lymph node involvement (presence vs absence) 0.022 (S) 6.293 2.749–9.271
Abbreviations: CI¼confidence interval; NS¼non-significant; pCTC¼positive circulating tumour cell; S¼significant; TNM¼tumour node metastasis.
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Figure 4 Overall survival analysis for 45 CRC patients with (A) CDX2
pCTCs p13.5 and (B) 45 CRC patients with CDX2 pCTCs 413.5.
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Figure 3 Overall survival analysis for 45 CRC patients with (A) CDX2
pCTCs p21.5 and (B) 45 CRC patients with CDX2 pCTCs 421.5.
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Figure 5 Disease-free survival analysis in CRC patients with (A) negative
preoperative CDX2 pCTC, (B) positive preoperative CDX2 pCTCs and
decreased postoperative level and (C) positive preoperative CDX2 pCTCs
and increased postoperative level.
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patients has opened up a new scenario in the detection of CTCs
(Wong et al, 2009). Although the sensitivity of CK20 pCTCs for
CRC was only 62%, other more sensitive and specific markers can
be explored using this refined IE assay. In this study, CDX2 pCTC
was chosen to be examined with three objectives because CDX2 is
both a sensitive and specific marker of intestinal differentiation
and it is overexpressed in CRC tumour cells when compared with
normal intestinal epithelium (Witek et al, 2005). The first objective
is to evaluate (1) the sensitivity of preoperative CDX2 pCTCs for
CRC and CAD, (2) the origin of those CDX2 pCTCs and (3) the
prognostic potential of preoperative CDX2 pCTCs. Our results
show that the overall detection rate in CRC was 81% and detailed
analysis indicated that the detection rates are higher for stages III
and IV CRC, whereas the detection rates are lower for stages I and
II CRC. These results are logical because the dissemination of
tumour cells into blood is a micrometastatic process, which has a
higher metastatic potential in stages III and IV tumours than in
stages I and II tumours (Payne, 1989). Moreover, our observation
is supported by a previous report, which showed that the CTCs are
the metastatic precursors with an increased malignant potential
when compared with the parental cells in the primary tumour
(Glinskii et al, 2003). On the other hand, preendoscopy CDX2
pCTCs can only be found in three CAD patients with severe
dysplasia; this low percentage (7.5%) is expected because CAD is a
pre-malignant lesion. In summary, our results suggest that the
presence of CDX2 pCTCs may be a late event in colorectal
carcinogenesis.
At 7 days after operation, CDX2 pCTC numbers were found to
be decreased in 67% (8 out 12) stage I, 47% (8 out of 17) stage II
and 95% (19 out of 20) stage III CRC patients. This finding
provides evidence that the origin of those preoperative CDX2
pCTCs is the primary tumour. Therefore, we suggest that CDX2
pCTC may be a better CRC biomarker than serum CEA because a
persistent high serum CEA level after surgery can be explained by
many reasons. The possible causes include overlooked metastases
or inadequate surgery (Duffy, 2001). However, smoking habits,
renal insufficiency, chronic pulmonary or liver diseases and
pancreatitis, as well as postoperative complications such as
mechanical bowel obstruction caused by surgery may also
contribute to this condition (Duffy, 2001; Wang et al, 2007).
Therefore, patients with high CEA concentration after surgery
should be thoroughly studied with the understanding that elevated
CEA often, but not always, predicts the recurrence of CRC (Filiz
et al, 2009). A rise in postoperative CEA levels before clinically
observable recurrence was reported in 18–75% of cases with CRC
relapse (Moertel et al, 1993). The survival analysis indicated that
there is no significant difference between patients with known and
unknown causes of high CEA levels; however, patients whose CEA
successfully returned to normal levels clearly showed a better
survival rate (Filiz et al, 2009). Collectively, these findings suggest
that early detection and operation would reduce CDX2 pCTCs,
which may diminish the risk of metastasis to other distant organs.
It is interesting to note that nine patients had an increase in CDX2
pCTCs after surgery for 7 days. We hypothesise that this
phenomenon may be due to the presence of residual tumour after
surgery. Follow-up of all TNM stage I–III CRC patients for 42
months showed that patients with increased postoperative CDX2
pCTC numbers had the worst DFS when compared with those with
decreased postoperative CDX2 pCTC numbers and those with
negative preoperative CDX pCTC. Therefore, CDX2 pCTCs may be
useful to select CRC patients with high risk of recurrence.
Moreover, our data provide evidence that CDX2 pCTC is a
potential marker to show the effectiveness of surgical resection or
other local treatment modalities, and a larger scale study to
compare CDX2 pCTC with a conventional CRC marker, such as
serum CEA, for validation of this important function will be
carried out. Overall, the detection rate of CDX2 pCTCs in various
TNM stages of CRC patients using this refined assay (81%) was
higher than that using CellSearch System in CRC patients by Sastre
et al (2008) (36.2%). This discrepancy can be explained by the fact
that Sastre et al (2008) performed blood collection after surgery in
TNM stage I–III CRC patients and that most of them had partial or
complete clearance of CTCs (Sastre et al, 2008). In fact, the
percentage of CDX2 pCTCs detected in our cohort of CRC patients
at their first follow-up after operation was only 62.5% (40 out of 64).
Another reason that can explain this difference in CRC patients is
that Sastre et al (2008) used X2 CTCs rather than X1 CTC in that
study as the cutoff point for positivity. In CAD patients, three
patients with severe dysplasia who had two, five and eight CDX2
pCTCs, respectively, before endoscopy showed no CDX2 pCTCs
after endoscopy, which suggests that the origin of those CDX2
pCTCs is the adenoma lesion. Our results support previous reports
that indicate that some CAD tissue specimens already have cancer
cell clones with unfavourable histology (Bertario et al, 2003;
Church, 2004; Jin et al, 2007). Therefore, early removal can prevent
them from changing into a malignant lesion later. Finally, the
absence of CDX2 pCTC in all 40 healthy subjects suggests that this
assay has a low false-positive rate.
The prognostic potential of CDX2 pCTCs is shown by its
significant correlation to TNM stage, lymph node status,
recurrence or metastasis. These results are expected because
during tumour growth, primary tumour cells will continuously
shed into the blood circulation and the lymphatic system. A small
number of tumour cells in the blood or the lymph may be able to
survive and metastasise to distant organs, such as liver or lung. In
addition, more tumour cells from TNM stages III and IV CRC
patients will shed into the blood and the lymph than those from
TNM stages I and II CRC patients because of the higher
proliferation rate in the advanced stage primary tumour (Valera
et al, 2005). Using the median CDX2 pCTC numbers of 21.5 as the
cutoff point, pretreatment CDX2 pCTCs correlated with OS in CRC
patients. Actually, the patients with CDX2 pCTCs 421.5 were
mainly of stages III and IV, whereas those with CDX2 pCTCs
p21.5 were mostly of stages I and II. This may be one explanation
why stages III and IV patients have a greater risk of recurrence,
metastasis and shorter survival than stages I and II patients.
Excluding stage IV CRC patients, the significant difference in OS
using the median CDX2 pCTC numbers of 13.5 shows that
preoperative CDX2 pCTC may predict survival. This finding,
together with the result that CRC patients with increasing
postoperative CDX2 has a worse DFS, shows that a portion of
CRC patients in our cohort, with both higher preoperative and
postoperative CDX2, had the worst OS and DFS.
In the second objective, we did not observe any pretreatment
CDX2 pCTC in patients with various kinds of BCD. This finding
can imply that those BCD do not have micrometastatic potential.
In fact, the significance of pretreatment CDX2 pCTC in CRC
detection would be greatly reduced if it were found in patients with
BCD. Therefore, we propose that patients with benign diseases
should be included in all tumour marker evaluation studies in
order to have a comprehensive assessment of the potential of the
markers in prognosis and diagnosis.
In the third objective, we explored whether CDX2 pCTCs can be
found in other cancers because currently one major limitation in IE
CTCs detection is that only broad-spectrum antibodies are used and
therefore detection is not specific to any kind of tumour or tissue
system. Previous studies indicated that IE CTCs detection using
broad spectrum antibody is very promising only in metastatic breast
cancer (Cristofanilli et al, 2004, 2005, 2006), whereas there are still
very scanty reports regarding CRC (Molnar et al, 2001; Allard et al,
2004; Sastre et al, 2008). Using this refined IE assay with
standardised ICC staining and stringent assessment criteria, CDX2
pCTC was only found in two prostate cancer patients. This finding
confirms previous studies that reported CDX2 expression in
prostate adenocarcinoma (Herawi et al, 2007; Leite et al,2 0 0 8 ) .
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this refined IE assay in CDX2 pCTCs detection is rather specific to
CRC among the types of cancers that have been tested.
To the best of our knowledge, this study is the first to detect
CDX2 pCTCs in CRC patients, using a GI-specific anti-CDX2
antibody. According to the American Society of Clinical Oncology
(ASCO) 2006 update of recommendations for the use of tumour
markers in GI cancer, serum CEA test can be ordered preopera-
tively if it would assist in staging and surgical planning (Locker
et al, 2006). Postoperative CEA levels should also be assessed every
3 months for stages II and III of the disease for at least 3 years if
the patient is a potential candidate for surgery or chemotherapy of
metastatic disease (Locker et al, 2006). Moreover, CEA is the
marker of choice for monitoring the response of metastatic disease
to systemic therapy (Locker et al, 2006). On the other hand, the
ASCO 2006 guidelines also admit that serum CEA test has
insufficient sensitivity for detecting primary and recurrent CRC
and this test may be useful as a first-line surveillance investigation
in CRC patients during surgical follow-up based on serial CEA
measurements, using temporal trends in conjunction with clinical,
radiological and/or histological confirmation (Locker et al, 2006;
Tan et al, 2009; Yamashita and Watanabe, 2009). Furthermore, the
ASCO guidelines comment that another CRC marker, carbo-
hydrate antigen 19.9, suffers from low sensitivity and specificity in
CRC and it has been proven ineffective as screening, diagnostic
and prognostic tools (Locker et al, 2006; Tan et al, 2009; Yamashita
and Watanabe, 2009). Therefore, it is necessary to develop novel
biomarkers for CRC detection and monitoring. Quantification of
CDX2 pCTCs, as detected by this refined IE assay, has high
potential for the differential diagnosis of CRC and their serial
measurements may be clinically useful to monitor disease
progression.
Finally, the success of this refined IE assay has opened up new
possibilities in the detection of CTCs as the shedding CTCs from
various cancers may be further characterised after IE with their
respective specific tumour markers, using ICC staining (Wong
et al, 2004), in situ hybridisation (Wong et al, 2002) or even
molecular profiling using quantum dot technology (Gao and Nie,
2003; Smith et al, 2006).
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